Yue Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yue Wang has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Qianqian Xue
Department of Pathology, Fudan University Shanghai Cancer Center
3 shared publicationsYan Jin
Department of Pathology, Fudan University Shanghai Cancer Center
3 shared publicationsLijun Chen
Department of Pathology, Fudan University Shanghai Cancer Center
2 shared publicationsQiang Zheng
Department of Pathology, Fudan University Shanghai Cancer Center
2 shared publications- Qiang Zheng
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
2 shared publications Xuxia Shen
Department of Pathology, Fudan University Shanghai Cancer Center
2 shared publications
Latest Publications
- Open Access
- 14 July 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (7) , 403
MET Exon 14 Skipping Mutations in Lung Cancer: Clinical–Pathological Characteristics and Immune Microenvironment
MET exon 14 skipping mutations have emerged as significant driver alterations in non-small-cell lung cancer (NSCLC), contributing to tumor progression. This study examines the immune microenvironment in NSCLC patients with these mutations and its prognostic implications. We performed multiplex immunofluorescence (mIF) staining on formalin-fixed paraffin-embedded (FFPE) tissue samples from nine NSCLC patients, including four recurrent/metastatic and five non-recurrent/non-metastatic patients. Two panels assessed immune cell markers (CD8, CD4, CD20, CD68, and FoxP3) and immune checkpoints (PD-L1, LAG3, and TIM3). Immune cell infiltration and checkpoint expression were analyzed using HALOTM software (version 3.6.4134.464). Nearest neighbor analysis was conducted to assess the proximity of immune cells to tumor cells. Univariate Cox regression analysis assessed factors associated with disease-free survival (DFS). CD8+TIM3+ and CD8+LAG3+ cells were predominantly located in the tumor parenchyma of recurrent/metastatic patients but localized to the stroma in non-recurrent/non-metastatic patients. Non-recurrent/non-metastatic patients exhibited a higher density of tertiary lymphoid structures and closer proximity of CD20+ B cells, CD8+TIM3+, and CD8+LAG3+ cells to tumor cells compared to recurrent/metastatic patients, though the differences were not statistically significant. Cox regression analysis suggested a potential association between higher densities of CD8+TIM3+ cells and improved DFS (HR = 0.89), though these findings did not reach statistical significance. Our findings suggest that differences in immune microenvironmental factors, particularly those related to immune checkpoint expression (TIM3 and LAG3), may influence clinical outcomes in NSCLC patients with MET exon 14 skipping mutations. Further studies are needed to validate these observations and explore potential therapeutic implications.
- 14 July 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (7) , 403
Open AccessMET Exon 14 Skipping Mutations in Lung Cancer: Clinical–Pathological Characteristics and Immune Microenvironment
MET exon 14 skipping mutations have emerged as significant driver alterations in non-small-cell lung cancer (NSCLC), contributing to tumor progression. This study examines the immune microenvironment in NSCLC patients with these mutations and its prognostic implications. We performed multiplex immunofluorescence (mIF) staining on formalin-fixed paraffin-embedded (FFPE) tissue samples from nine NSCLC patients, including four recurrent/metastatic and five non-recurrent/non-metastatic patients. Two panels assessed immune cell markers (CD8, CD4, CD20, CD68, and FoxP3) and immune checkpoints (PD-L1, LAG3, and TIM3). Immune cell infiltration and checkpoint expression were analyzed using HALOTM software (version 3.6.4134.464). Nearest neighbor analysis was conducted to assess the proximity of immune cells to tumor cells. Univariate Cox regression analysis assessed factors associated with disease-free survival (DFS). CD8+TIM3+ and CD8+LAG3+ cells were predominantly located in the tumor parenchyma of recurrent/metastatic patients but localized to the stroma in non-recurrent/non-metastatic patients. Non-recurrent/non-metastatic patients exhibited a higher density of tertiary lymphoid structures and closer proximity of CD20+ B cells, CD8+TIM3+, and CD8+LAG3+ cells to tumor cells compared to recurrent/metastatic patients, though the differences were not statistically significant. Cox regression analysis suggested a potential association between higher densities of CD8+TIM3+ cells and improved DFS (HR = 0.89), though these findings did not reach statistical significance. Our findings suggest that differences in immune microenvironmental factors, particularly those related to immune checkpoint expression (TIM3 and LAG3), may influence clinical outcomes in NSCLC patients with MET exon 14 skipping mutations. Further studies are needed to validate these observations and explore potential therapeutic implications.
- 26 June 2023
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 47 (9) , 1059-1066
POU2F3
POU2F3 (POU class 2 homeobox 3) is a novel transcription factor used to define the special molecular subtype of small cell lung cancer (SCLC) known as SCLC-P. Nevertheless, the sensitivity and specificity of POU2F3 immunohistochemical (IHC) staining have not been fully investigated. In this study, we explored the expression of POU2F3 by IHC in a large cohort of SCLC clinical samples (n=246), other common lung cancer types (n=2207), and various other cancer types (n=194). The results showed that POU2F3 was strongly nuclear stained in 13.41% (33/246) of SCLC cases, with negative or minimal labeling for thyroid transcription factor-1 and neuroendocrine (NE) markers. Compared with POU2F3-negative SCLC, SCLC-P harbored fewer TP53 and RB1 mutations. POU2F3 was also expressed in 3.13% (8/256) of squamous cell carcinomas (SCCs) and 20% (2/10) of large cell NE carcinomas (LCNECs), whereas other lung cancer types were negative. In addition to lung cancer, POU2F3 was positive in 22.2% (4/18) of thymic tumors. All other tumors were POU2F3-negative except for thymic carcinoma, although sparsely distributed weak nuclear staining was observed in lung adenocarcinoma, cervical SCC, and colorectal carcinoma. The sensitivity and specificity of POU2F3 in NE-low/negative SCLC were 82.1% and 99.4%, respectively. Notably, some rare unique patterns of POU2F3 expression were observed. One case of thymic SCC was characterized by diffuse and uniform cytomembrane staining. One case of esophageal NE tumor was nuclear-positive, while the normal proliferating squamous epithelium was strongly membrane-stained. This is the largest cohort of clinical samples to confirm that POU2F3 is a highly sensitive and specific diagnostic marker for NE-low/negative SCLC.
- 26 June 2023
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 47 (9) , 1059-1066
POU2F3
POU2F3 (POU class 2 homeobox 3) is a novel transcription factor used to define the special molecular subtype of small cell lung cancer (SCLC) known as SCLC-P. Nevertheless, the sensitivity and specificity of POU2F3 immunohistochemical (IHC) staining have not been fully investigated. In this study, we explored the expression of POU2F3 by IHC in a large cohort of SCLC clinical samples (n=246), other common lung cancer types (n=2207), and various other cancer types (n=194). The results showed that POU2F3 was strongly nuclear stained in 13.41% (33/246) of SCLC cases, with negative or minimal labeling for thyroid transcription factor-1 and neuroendocrine (NE) markers. Compared with POU2F3-negative SCLC, SCLC-P harbored fewer TP53 and RB1 mutations. POU2F3 was also expressed in 3.13% (8/256) of squamous cell carcinomas (SCCs) and 20% (2/10) of large cell NE carcinomas (LCNECs), whereas other lung cancer types were negative. In addition to lung cancer, POU2F3 was positive in 22.2% (4/18) of thymic tumors. All other tumors were POU2F3-negative except for thymic carcinoma, although sparsely distributed weak nuclear staining was observed in lung adenocarcinoma, cervical SCC, and colorectal carcinoma. The sensitivity and specificity of POU2F3 in NE-low/negative SCLC were 82.1% and 99.4%, respectively. Notably, some rare unique patterns of POU2F3 expression were observed. One case of thymic SCC was characterized by diffuse and uniform cytomembrane staining. One case of esophageal NE tumor was nuclear-positive, while the normal proliferating squamous epithelium was strongly membrane-stained. This is the largest cohort of clinical samples to confirm that POU2F3 is a highly sensitive and specific diagnostic marker for NE-low/negative SCLC.
- 2 March 2023
- Published by Wiley in Histopathology
- Vol. 83 (2) , 178-192
Frequent EGFR exon 20 insertion in the so‐called peripheral‐type squamous cell neoplasm of uncertain malignant potential: a variant of bronchiolar adenoma or under‐recognised entity?
Introduction: Herein we describe a series of rare peripheral pulmonary neoplasms temporarily termed “peripheral type squamous cell neoplasm of uncertain malignant potential (PSCN‐UMP)” and investigate their relationship to bronchiolar adenoma (BA) and squamous cell carcinoma (SCC).Materials and Methods: The histologic and immunohistochemical features of 10 PSCN‐UMPs and six BAs were compared. Whole exome sequencing (WES) and bioinformatics analysis were performed to further compare the genetic features of PSCN‐UMPs, BAs, and NSCLCs.Results: All PSCN‐UMPs were peripherally located and histologically characterised by the lepidic, nested, and papillary proliferation of relatively bland squamous cells, accompanied by entrapped hyperplastic reactive pneumocytes. The basal squamous cells coexpressed TTF1 and squamous markers. Both cellular components exhibited bland morphology and a low proliferative activity. The six BAs met the morphologic and immunophenotypic features of proximal‐type BA. Genetically, driver mutations, including frequent EGFR exon 20 insertions, were found in PSCN‐UMPs, while the KRAS mutation, BRAF mutation, and ERC1::RET fusion were detected in BAs. PSCN‐UMPs also shared some alterations with BAs in mutational signatures, while copy number variants (CNV) were enriched in MET and NKX2‐1 in PSCN‐UMP and MCL1, MECOM, SGK1, and PRKAR1A in BA.Conclusion: PSCN‐UMPs exhibited the proliferation of bland squamous cells accompanied by entrapped pneumocytes and frequent EGFR exon 20 insertions, which showed distinct features from BAs and SCCs. Recognition of this specific entity will help to expand the morphologic and molecular spectrum of peripheral lung squamous neoplasms.
- 2 March 2023
- Published by Wiley in Histopathology
- Vol. 83 (2) , 178-192
Frequent EGFR exon 20 insertion in the so‐called peripheral‐type squamous cell neoplasm of uncertain malignant potential: a variant of bronchiolar adenoma or under‐recognised entity?
Introduction: Herein we describe a series of rare peripheral pulmonary neoplasms temporarily termed “peripheral type squamous cell neoplasm of uncertain malignant potential (PSCN‐UMP)” and investigate their relationship to bronchiolar adenoma (BA) and squamous cell carcinoma (SCC).Materials and Methods: The histologic and immunohistochemical features of 10 PSCN‐UMPs and six BAs were compared. Whole exome sequencing (WES) and bioinformatics analysis were performed to further compare the genetic features of PSCN‐UMPs, BAs, and NSCLCs.Results: All PSCN‐UMPs were peripherally located and histologically characterised by the lepidic, nested, and papillary proliferation of relatively bland squamous cells, accompanied by entrapped hyperplastic reactive pneumocytes. The basal squamous cells coexpressed TTF1 and squamous markers. Both cellular components exhibited bland morphology and a low proliferative activity. The six BAs met the morphologic and immunophenotypic features of proximal‐type BA. Genetically, driver mutations, including frequent EGFR exon 20 insertions, were found in PSCN‐UMPs, while the KRAS mutation, BRAF mutation, and ERC1::RET fusion were detected in BAs. PSCN‐UMPs also shared some alterations with BAs in mutational signatures, while copy number variants (CNV) were enriched in MET and NKX2‐1 in PSCN‐UMP and MCL1, MECOM, SGK1, and PRKAR1A in BA.Conclusion: PSCN‐UMPs exhibited the proliferation of bland squamous cells accompanied by entrapped pneumocytes and frequent EGFR exon 20 insertions, which showed distinct features from BAs and SCCs. Recognition of this specific entity will help to expand the morphologic and molecular spectrum of peripheral lung squamous neoplasms.
- 15 September 2020
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Biomedical and Health Informatics
- Vol. 25 (5) , 1673-1685
Weakly Supervised Histopathology Image Segmentation With Sparse Point Annotations
Digital histopathology image segmentation can facilitate computer-assisted cancer diagnostics. Given the difficulty of obtaining manual annotations, weak supervision is more suitable for the task than full supervision is. However, most weakly supervised models are not ideal for handling severe intra-class heterogeneity and inter-class homogeneity in histopathology images. Therefore, we propose a novel end-to-end weakly supervised learning framework named WESUP. With only sparse point annotations, it performs accurate segmentation and exhibits good generalizability. The training phase comprises two major parts, hierarchical feature representation and deep dynamic label propagation. The former uses superpixels to capture local details and global context from the convolutional feature maps obtained via transfer learning. The latter recognizes the manifold structure of the hierarchical features and identifies potential targets with the sparse annotations. Moreover, these two parts are trained jointly to improve the performance of the whole framework. To further boost test performance, pixel-wise inference is adopted for finer prediction. As demonstrated by experimental results, WESUP is able to largely resolve the confusion between histological foreground and background. It outperforms several state-of-the-art weakly supervised methods on a variety of histopathology datasets with minimal annotation efforts. Trained by very sparse point annotations, WESUP can even beat an advanced fully supervised segmentation network.
- 15 September 2020
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Biomedical and Health Informatics
- Vol. 25 (5) , 1673-1685
Weakly Supervised Histopathology Image Segmentation With Sparse Point Annotations
Digital histopathology image segmentation can facilitate computer-assisted cancer diagnostics. Given the difficulty of obtaining manual annotations, weak supervision is more suitable for the task than full supervision is. However, most weakly supervised models are not ideal for handling severe intra-class heterogeneity and inter-class homogeneity in histopathology images. Therefore, we propose a novel end-to-end weakly supervised learning framework named WESUP. With only sparse point annotations, it performs accurate segmentation and exhibits good generalizability. The training phase comprises two major parts, hierarchical feature representation and deep dynamic label propagation. The former uses superpixels to capture local details and global context from the convolutional feature maps obtained via transfer learning. The latter recognizes the manifold structure of the hierarchical features and identifies potential targets with the sparse annotations. Moreover, these two parts are trained jointly to improve the performance of the whole framework. To further boost test performance, pixel-wise inference is adopted for finer prediction. As demonstrated by experimental results, WESUP is able to largely resolve the confusion between histological foreground and background. It outperforms several state-of-the-art weakly supervised methods on a variety of histopathology datasets with minimal annotation efforts. Trained by very sparse point annotations, WESUP can even beat an advanced fully supervised segmentation network.